ArticleJournal of inflammation research2026
Electroacupuncture Inhibits the Early Neuroinflammatory Cascade Triggered by TLR2 in the Prodromal Period of PD.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neuroprotective Role of E3 Ubiquitin Ligase TRIM2 in Parkinson's Disease: Attenuation of Oxidative Stress and Apoptosis via Promoting ELAVL1 Ubiquitination.CNS neuroscience & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore electroacupuncture (EA)'s effect and mechanism in alleviating prodromal Parkinson's disease (pPD) by targeting TLR2-mediated neuroinflammation. Methods: Rat pPD models were established via striatal 10 μg/4 μL 6-OHDA injection. EA was applied at DU20, EX-HN3, LR2, and LR3 for 14 days. Behavioral tests, ELISA, immunohistochemistry, immunofluorescence, Western blot and qRT-PCR were used to assess non-motor symptoms, DA/TH levels, TLR2 expression, microglial activation, TLR2/NF-κB/NLRP3 pathway and pyroptosis. Results: 6-OHDA induced 30-40% striatal DA reduction and typical pPD non-motor symptoms. EA significantly improved these symptoms, reduced TLR2 expression in key regions (substantia nigra, hippocampus, etc), inhibited M1 microglial activation (decreased CD86, increased CD206), and suppressed TLR2/NF-κB/NLRP3 pathway-related proteins, and inhibits microglial pyroptosis. Conclusion: EA inhibited the neuroinflammation and microglial cell activation as well as pyroptosis mediated by TLR2, thereby alleviating the non-motor symptoms of PD. This provides a potential possibility for the intervention treatment of PD to prevent the progression of the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.